Corea Therapeutics Overview
CT owns a platform allowing instant modification of various immune cells into tumor-targeted immunotherapy
Contact Information
Address: 12456 N Piping Rock Rd
URL: coreatherapeutics.com
CT owns a platform allowing instant modification of various immune cells into tumor-targeted immunotherapy
Address: 12456 N Piping Rock Rd
URL: coreatherapeutics.com
Conventional combinatorial anticancer therapy has shown promising outcomes; still, a significant interest in developing new methods to reinforce and possibly merge chemotherapy and immunotherapy persists. Here, we present a new one-step method that immediately modifies immune cells into a targeted form of chemoimmunotherapy through spontaneous and rapid incorporation of hydrophobized antibody-drug conjugates (ADCs) on the surface of immune cells. Therapeutic objectives of our approach included targeted delivery of a potent chemotherapeutic agent to avoid adverse effects, enhancing the mobilization of infused immune cells toward tumor sites, and preserving the intense cytotoxic activities of immune cells against tumor cells. The embedding of hydrophobized ADCs on the immune cell membrane using our strategy provided non-invasive, non-toxic, and homogenous modifications that transiently arm immune cells with highly potent cytotoxic drugs targeted towards cancer cells. The resulting surface-engineered immune cells with ADCs significantly suppressed the tumor growth and drive the eradication of target cancer cells through combinatorial anticancer effects. This novel strategy allows convenient and timely preparation of advanced chemoimmunotherapy on a single immune cell to treat various types of cancer.
We developed a one-step method that spontaneously transforms non-specific immune cells into a new form of targeted chemoimmunotherapy through the introduction of ADCs or mAbs on the surface of an active immune cell. The process of embedding ADCs on the immune cell surface exploits the hydrophobic interaction between a polymeric lipid chain and the lipid bilayer of the cell membrane. Likewise, lipid-conjugated ADCs (hydrophobized ADCs) can be readily incorporated into the lipid bilayer without disrupting the cell membrane integrity and award new functions to the surface-engineered cells. The surface-engineered immune cells containing ADCs could simultaneously deliver potent chemotherapeutic agents to the target tumor and enhance the homing of adoptively transferred immune cells toward the tumor sites without compromising their cytotoxic activities, ultimately intensifying the combinatorial anticancer efficacy to combat cancer.